News

US FDA Grants Emergency Use Authorisation For ViraDx™

September 11, 2023

MELBOURNE, Australia (11 Sep 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that the US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) … Continued

READ MORE
July 3, 2023

Lumos Receives US FDA Clearance for FebriDx®

MELBOURNE, Australia (3 July 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that it has received clearance from the US Food and Drug Administration (FDA) to … Continued

READ MORE
June 28, 2022

ViraDx™ Receives Interim Order Authorization from Health Canada

Lumos Diagnostics Introduces 15-minute ViraDx™ Test for COVID-19, Flu A and Flu B.

READ MORE
June 21, 2022

Lumos Diagnostics Appoints Doug Ward As CEO

Ward to lead U.S. FebriDx launch pending FDA 510(k) clearance.

READ MORE
November 3, 2021

Lumos Diagnostics Receives Authorization for CoviDx™ SARS-CoV-2 Rapid Antigen Test in Canada

MELBOURNE, VIC. (03 November 2021): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Health Canada has granted Interim Order authorization for the Lumos CoviDx™ SARS-CoV-2 Rapid Antigen Test. The CoviDx test gives qualified … Continued

READ MORE
October 24, 2021

Box Hill Hospital Emergency Department Initiates Trial Using FebriDx®

MELBOURNE, VIC. (24 October 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® … Continued

READ MORE
October 6, 2021

Economic Evaluation of Lumos Diagnostics’ FebriDx® Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

SARASOTA, Fla. (October 6, 2021) – Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Journal of Health Economics and Outcomes Research (JHEOR) has published an economic study that concludes using the FebriDx® … Continued

READ MORE

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.